Inventor · disambiguated record
Paul Allen Sutton
Also filed as: SUTTON PAUL A · SUTTON PAUL ALLEN
18 granted patents·20 pending applications·150 citations·filing 2003–2024
94Inventor score
Top patents by PatentIndex Score
38 records- 0196US8877938B2Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2006·Granted Nov 4, 2014·44 cites·14 claims
- 0294US8163904B2Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-BenzamideMANLEY PAUL W·Filed 2006·Granted Apr 24, 2012·32 cites·4 claims
- 0392US8389537B2Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideMANLEY PAUL W·Filed 2012·Granted Mar 5, 2013·17 cites·2 claims
- 0491US2025339395A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2024·Application pending·0 cites
- 0589US8415363B2Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideMANLEY PAUL W·Filed 2012·Granted Apr 9, 2013·15 cites·8 claims
- 0688US8580806B2Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideNOVARTIS AG·Filed 2013·Granted Nov 12, 2013·9 cites·2 claims
- 0788US8343984B2Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideNOVARTIS AG·Filed 2006·Granted Jan 1, 2013·11 cites·14 claims
- 0886US9388134B2Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2014·Granted Jul 12, 2016·5 cites·15 claims
- 0986US9163005B2Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideNOVARTIS AG·Filed 2013·Granted Oct 20, 2015·6 cites·1 claims
- 1086US8829015B2Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideNOVARTIS AG·Filed 2013·Granted Sep 9, 2014·7 cites·2 claims
- 1184US11642329B2Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Granted May 9, 2023·0 cites·2 claims
- 1283US2022257551A1Amorphous solid form of compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Application pending·0 cites
- 1381US11096918B2Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2019·Granted Aug 24, 2021·0 cites·2 claims
- 1479US2021361610A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2021·Application pending·0 cites
- 1572US8202998B2Salts of benzimidazolyl pyridyl ethers and formulations thereofGULLAPALLI RAMPURNA·Filed 2007·Granted Jun 19, 2012·2 cites·3 claims
- 1672US2019374498A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1772US2019374497A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1869US2018344679A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1965US7247746B2Crystal forms of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanineNOVARTIS AG·Filed 2003·Granted Jul 24, 2007·1 cites·7 claims
- 2064US8829194B2Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acidSUTTON PAUL ALLEN·Filed 2011·Granted Sep 9, 2014·1 cites·17 claims
- 2162US2016324821A1Compounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2016·Application pending·0 cites
- 2261US2014343087A1Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideMANLEY PAUL W·Filed 2014·Application pending·0 cites
- 2360US2008319222A1Crystal forms of N- (trans-4-isopropylctyclohexylcarbonyl) -D-phenylalanineSUTTON PAUL A·Filed 2008·Application pending·0 cites
- 2458US2008081927A1Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanineSUTTON PAUL A·Filed 2007·Application pending·0 cites
- 2557US9334276B2Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitorNOVARTIS AG·Filed 2013·Granted May 10, 2016·0 cites·1 claims
- 2652US2008299190A1Direct Compression Formulation and ProcessNOVARTIS AG·Filed 2006·Application pending·0 cites
- 2750US8501785B2Salts of benzimidazolyl pyridyl ethers and formulations thereofGULLAPALLI RAMPURNA·Filed 2012·Granted Aug 6, 2013·0 cites·24 claims
- 2850US2009143469A1Salts of nateglinideSUTTON PAUL ALLEN·Filed 2009·Application pending·0 cites
- 2948US2006035941A1Calcium salts of indole derived statinsCHEN GUANG-PEI·Filed 2003·Application pending·0 cites
- 3047US2014343102A1Crystalline forms of the sodium salt of (4--cyclohexyl)-acetic acidSUTTON PAUL ALLEN·Filed 2014·Application pending·0 cites
- 3146US2006210627A1Direct compression formulation and processPFEFFER SABINE·Filed 2006·Application pending·0 cites
- 3245US8865897B2Crystal modifications-3-(1H-indol-3-yl)-4- [4-methyl-piperazin-1-yl)-quinazolin-4-yl] -pyrrole-2, 5-D ioneKARPINSKI PIOTR·Filed 2007·Granted Oct 21, 2014·0 cites·9 claims
- 3345US2005234129A1Salts of nateglinideSUTTON PAUL A·Filed 2003·Application pending·0 cites
- 3442US2010249204A1Calcium salts of indole derived statinsCHEN GUANG-PEI·Filed 2010·Application pending·0 cites
- 3542US2012015029A1Direct compression formulation and processPFEFFER SABINE·Filed 2011·Application pending·0 cites
- 3638US11786498B2Sacubitril calcium saltsNOVARTIS AG·Filed 2015·Granted Oct 17, 2023·0 cites·12 claims
- 3736US2016176883A1Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitorSUTTON PAUL ALLEN·Filed 2016·Application pending·0 cites
- 3831US2013338061A1Salts and Polymorphs of Sulfamide NS3 InhibitorsSHAH LIPA·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Paul Allen Sutton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →